[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 3 sources · 15 days · First seen · Last updated

Lenacapavir HIV prevention rollout and efficacy

Overview

Lenacapavir, a long-acting injectable medication for HIV pre-exposure prophylaxis (PrEP), has demonstrated high efficacy in clinical trials. The drug, which requires only two doses per year, was administered via abdominal injection to ensure better adherence compared to traditional daily oral regimens.

Clinical trials PURPOSE 1 and PURPOSE 2 yielded results so significant that an independent monitoring committee recommended stopping the randomized phases early. Following these findings, researchers provided the medication to participants in the placebo groups.

In Kenya, the rollout of lenacapavir aims to improve access equity in low- and middle-income countries. Health officials have noted the drug’s potential to simplify prevention for high-risk individuals, though they emphasize the necessity of health-system readiness for sustainable delivery.

Entities

lenacapavir · Githinji Gitahi · PURPOSE 2 · Kenya · Broadly neutralising antibodies

Timeline

  1. about 16 hours ago

    [HEALTH] 3 sources
    Lenacapavir shows high efficacy in HIV prevention clinical trials

    The HIV prevention drug lenacapavir has shown unprecedented efficacy in clinical trials, offering a twice-yearly injection that improves adherence compared to daily oral PrEP regimens.

  2. 15 days ago

    [HEALTH] 2 sources
    Kenya rolls out long‑acting injectable HIV prevention Lenacapavir

    Kenya launches lenacapavir injectable HIV prevention, reducing doses to twice a year, while research shows broadly neutralising antibodies can extend viral control in a subset of patients.

Sources

kpbs.org · ksfr.org · nprinternedition.org